ICE regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Carboplatin/Etoposide/Ifosfamide; CBDCA/IFF/VP-16; ICE; ICE Regimen; ICE regimen; Ifosfamide-Carboplatin-Etoposide Regimen
Overview
ICE regimen refers to a chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of non-Hodgkin and hodgkin lymphomas.[1][2]
Regimen
IIfosfamide
CCarboplatin
EEtoposide
Indications
- Relapsed and refractory non-Hodgkin and Hodgkin lymphomas.[1]
References
- ↑ 1.0 1.1 Xia W, Ma CK, Reid C, Bai L, Wong K, Kerridge I; et al. (2014). “Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation”. J Clin Apher. 29 (6): 322–30. doi:10.1002/jca.21340. PMID 24944079.
- ↑ “NCI Thesaurus”.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH